Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Rituximab in Heart Failure With Reduced Ejection Fraction
NCT03332888Phase 2Unknown
- Sponsor
- Hospital Zambrano Hellion
- Start
- Jan 2021
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of rituximab in heart failure with reduced ejection fraction (HFrEF), sponsored by Hospital Zambrano Hellion. Primary endpoint: Incidence of Rituximab Emergent Cardiovascular Adverse Events at 6 months. Status: unknown.
02
Drugs
rituximab
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03332888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332888.